Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.
Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →
AI Takeaway
Revvity's fiscal second quarter was shaped by a one-time tariff refund that reduced cost of revenue and expanded gross margin, but higher restructuring charges associated with workforce reductions and facility consolidations pressured operating income. The Diagnostics segment posted solid revenue growth and a 520-basis-point margin expansion, while the Life Sciences segment was weighed down by lower software sales. A $16.2 million tariff refund, recorded upon receipt, provided a partial uplift, yet the company incurred $35.5 million in restructuring costs as part of its streamlining efforts. These factors, combined with digital investments and an increase in SG&A, resulted in a modest decline in operating income despite top-line growth.
Revenue
$729.69M
+1.31% YoY
EPS (Diluted)
$0.47
+2.17% YoY
Operating Income
$89.32M
-1.59% YoY
Source: SEC XBRL
Revvity (RVTY) reported Q2 FY2026 revenue of $729.69M, up 1.3% year over year. Operating margin was 12.2%, down 0.4 points from 12.6% a year earlier. RVTY's fiscal Q2 FY2026 corresponds to calendar Q3 2026.
Last 4 quarters: 4 beats
| Quarter | Actual EPS (USD) | Consensus (USD) | Result |
|---|---|---|---|
| Jun 2026 | 1.41 | 1.25 | Beat +13.1% |
| Mar 2026 | 1.06 | 1.04 | Beat +2.3% |
| Dec 2025 | 1.70 | 1.58 | Beat +7.4% |
| Sep 2025 | 1.18 | 1.16 | Beat +1.7% |
2 reported segments · SEC XBRL
Segment revenue totals $729.69M, which is the $729.69M of consolidated revenue on the income statement.
Compiled by AI from 10-Q Item 2 of this filing
Revvity recognized $16.2 million in tariff refunds during Q2 FY2026 after the U.S. Supreme Court ruled that tariffs imposed under IEEPA were not authorized. The refunds were recorded upon receipt, reducing cost of revenue. An additional $4.0 million of refunds may be recognized if approved.
Source: 10-Q Item 2 MD&A
Restructuring and other costs rose to $35.5 million from $11.2 million in the prior-year quarter, driven by workforce reductions affecting approximately 3% of employees and facility consolidations aimed at streamlining operations.
Source: 10-Q Item 2 MD&A
Diagnostics segment operating margin expanded 520 basis points year over year, benefiting from the tariff refund and cost containment, while Life Sciences margin contracted 50 basis points due to strategic software investments and new product development.
Source: 10-Q Item 2 MD&A
The effective tax rate decreased to 15.8% from 19.6% in the prior-year quarter, primarily due to $2.4 million in favorable state deferred tax remeasurements.
Source: 10-Q Item 2 MD&A
Subsequent to Q2 FY2026, the company repaid its €500 million 1.875% Senior Unsecured Notes upon maturity, using existing cash and borrowing capacity.
Source: 10-Q Item 2 MD&A
Compiled by AI from 10-Q Item 1A of this filing · 2 high, 3 medium, 0 low
Changes in U.S. funding priorities, trade policies, and regulatory environments have created a more cautious spending environment for healthcare and research customers, potentially reducing demand for Revvity's products. Budget cuts or freezes could further pressure sales.
Source: 10-Q Item 1A Risk Factors
Imposition of tariffs and retaliatory measures can increase costs for raw materials and components, disrupt supply chains, and affect product pricing. The recent Supreme Court ruling and ongoing refund processes highlight the volatility and uncertainty in trade policy.
Source: 10-Q Item 1A Risk Factors
Rapid technological change requires continuous innovation; failure to introduce new products in a timely manner or accurately anticipate customer needs could lead to loss of market share to competitors with greater R&D resources.
Source: 10-Q Item 1A Risk Factors
Integrating acquisitions, such as Advanced Chemistry Development, and executing divestitures like the China Immunodiagnostics business, involve execution risks, potential cost overruns, and distraction of management, which could disrupt ongoing operations.
Source: 10-Q Item 1A Risk Factors
Reliance on centralized IT systems exposes Revvity to potential breaches, cyberattacks, or system failures that could lead to data loss, operational disruption, ransom demands, or reputational harm.
Source: 10-Q Item 1A Risk Factors
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue $M | 729.69 $M | 720.28 $M | +1.31% |
Cost of Revenue $M | 312.82 $M | 327.73 $M | -4.55% |
Operating Income $M | 89.32 $M | 90.76 $M | -1.59% |
Net Income $M | 51.82 $M | 53.95 $M | -3.94% |
EPS (Basic) $ | 0.47 $ | 0.46 $ | +2.17% |
EPS (Diluted) $ | 0.47 $ | 0.46 $ | +2.17% |
R&D Expense $M | 48.97 $M | 53.27 $M | -8.06% |
SG&A Expense $M | 278.58 $M | 248.53 $M | +12.09% |
Answers draw on this SEC filing and the data on this page
RVTY delivered 7.0% revenue growth to $711.1M in Q2 2026, but net income slipped 3.6% to $40.7M as cost of revenue rose faster than sales and cash balances declined 24.4% year-over-year.
RVTY delivered modest revenue growth of 3.7% to $2.86B in FY2025, but net income declined 10.8% to $241.2M as higher R&D spending, increased current liabilities, and aggressive share buybacks of $820.8M weighed on profitability and cash balances.
Other companies in Health Care Equipment